◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Home › All stocks › A › ABVX

Abivax SA American Depositary Shares (ABVX) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-11-04

Abivax SA American Depositary Shares (ABVX) operates in the BIOTECHNOLOGY industry and is headquartered in Paris, France with about 98 employees. Its market capitalization is roughly $8 billion. In the fiscal year ended 2025-12-31, ABVX reported €0M in revenue and (€336M) in net income.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.

Interactive charts & full statements → Open the ABVX valuation workbench →

ABVX Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-03-312025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Total Revenue€0M€0M€11M€5M€5M€0M€0M€0M€0M€0M€0M€0M€0M€0M
Gross Profit—(€1M)€11M€5M(€51M)(€46M)(€34M)(€28M)(€15M)(€14M)(€15M)€0M(€3M)(€6M)
Gross Margin %——100.0%99.0%-1107.7%-123018.9%-53623.8%-1409300.0%-85327.8%-144970.0%-11431.5%-721.4%-23321.4%-7516.1%
Operating Income (EBIT)(€383M)(€246M)(€173M)(€127M)(€65M)(€41M)(€38M)(€33M)(€19M)(€14M)(€18M)(€18M)(€5M)(€7M)
Operating Margin %——-1602.9%-2756.5%-1414.7%-111891.9%-60330.2%-1664800.0%-106155.6%-141500.0%-14359.1%-43464.3%-36100.0%-10003.6%
Net Income(€538M)(€336M)(€176M)(€148M)(€61M)(€42M)(€38M)(€31M)(€16M)(€11M)(€14M)(€16M)(€5M)(€6M)
Net Margin %——-1633.1%-3197.1%-1325.3%-114735.1%-59604.8%-1531700.0%-87905.6%-112230.0%-11266.1%-37985.7%-36285.7%-7970.2%
EBITDA—(€301M)(€163M)(€133M)(€53M)(€39M)(€38M)(€33M)(€19M)(€14M)(€18M)(€18M)(€5M)(€7M)
Earnings Per Share (EPS)€-7.48€-4.83€-2.80€-3.43€-3.18€-2.75€-2.62€-2.51€-1.55€-1.13€-1.47€-1.64€-0.55€-0.64
Shares Outstanding (M)79M70M63M43M19M15M14M12M10M10M10M10M9M9M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ABVX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Total Revenue€0M€0M(€2M)€0M€2M€0M€7M€0M€3M
Gross Profit——(€3M)—€2M—€7M—€3M
Gross Margin %——151.0%—100.0%—100.0%—100.0%
Operating Income (EBIT)(€84M)(€56M)(€200M)(€81M)(€46M)(€47M)(€47M)(€50M)(€35M)
Operating Margin %——9893.9%—-2305.2%—-637.9%—-1041.1%
Net Income(€117M)(€48M)(€288M)(€153M)(€48M)(€52M)(€52M)(€55M)(€39M)
Net Margin %——14263.2%—-2400.3%—-707.8%—-1142.7%
EBITDA——(€256M)—(€45M)—(€48M)—(€35M)
Earnings Per Share (EPS)€-1.47€-0.61€-4.14€-1.97€-0.76€-0.83€-0.83—€-0.62
Shares Outstanding (M)—79M70M78M63M63M63M—63M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ABVX Free Cash Flow History

Cash flowTTM → 2026-03-312025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
Cash from Operations (CFO)(€226M)(€156M)(€154M)(€100M)(€54M)(€45M)(€30M)(€27M)(€15M)(€8M)(€16M)(€15M)(€3M)
Capital Expenditures (CapEx)€0M€0M€1M€0M€0M€0M€1M€1M€1M€1M€1M€1M€0M
Free Cash Flow (FCF)(€227M)(€156M)(€155M)(€100M)(€54M)(€45M)(€31M)(€28M)(€15M)(€9M)(€16M)(€16M)(€3M)
FCF Margin %——-1433.6%-2170.0%-1183.9%-121878.4%-48763.5%-1420700.0%-85366.7%-94280.0%-12857.5%-37926.2%-23915.6%

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ABVX Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Cash from Operations (CFO)(€52M)(€51M)(€71M)(€71M)(€33M)(€33M)(€33M)(€35M)(€50M)
Capital Expenditures (CapEx)€0M€0M€0M€0M€0M€0M€0M€0M€0M
Free Cash Flow (FCF)(€52M)(€51M)(€71M)(€71M)(€33M)(€33M)(€33M)(€36M)(€51M)
FCF Margin %——3534.5%—-1653.9%—-450.4%—-1492.7%

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ABVX Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Total Assets€462M€584M€205M€327M€76M€109M€71M€52M€54M€54M€61M€76M€38M€38M
Cash & Cash Equivalents€388M€516M€144M€252M€27M€61M€29M€10M€8M€2M€8M€25M€1M€3M
Total Liabilities€96M€129M€165M€131M€68M€83M€53M€33M€19M€6M€4M€4M€4M€4M
Total Debt (Short + Long-Term)—€29M€96M€76M€67M€64M€28M€41M€11M€0M€0M€0M€0M€0M
Total Shareholders' Equity€366M€455M€41M€196M€7M€26M€18M€19M€35M€48M€57M€72M€34M€34M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ABVX viewer.

Other Companies in BIOTECHNOLOGY

← ABVCAll “A” companiesABX →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.